(c) 2024 PillSync.com

dextroamphetamine saccharate amphetamine aspartate dextroamphetamine sulfate and amphetamine sulfate dextroamphetamine saccharate amphetamine aspartate dextroamphetamine sulfate and amphetamine sulfate tablet

INDICATIONS Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablets are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and Narcolepsy. attention deficit hyperactivity disorder (ADHD) A diagnosis of attention deficit hyperactivity disorder (ADHD; DSM-IV ® ) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months; fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; "on the go;" excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met. Special Diagnostic Considerations Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of the required number of DSM-IV ® characteristics. Need for Comprehensive Treatment Program Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician's assessment of the chronicity and severity of the child's symptoms. Long-Term Use The effectiveness of dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate for long-term use has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Mutual Pharmaceutical Company


2 years ago ROUND YELLOW MP 447 dextroamphetamine saccharate amphetamine aspartate dextroamphetamine sulfate and amphetamine sulfate dextroamphetamine saccharate amphetamine aspartate dextroamphetamine sulfate and amphetamine sulfate tablet

ROUND YELLOW MP 447

2 years ago ROUND YELLOW MP 447 dextroamphetamine saccharate amphetamine aspartate dextroamphetamine sulfate and amphetamine sulfate dextroamphetamine saccharate amphetamine aspartate dextroamphetamine sulfate and amphetamine sulfate tablet

MP 447 ROUND YELLOW

HOW SUPPLIED Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablets 5 mg, round, green, double-scored, debossed MP 441 on one side; the other side plain Bottles of 100 NDC 53489-564-01 Bottles of 250 NDC 53489-564-03 Bottles of 500 NDC 53489-564-05 Bottles of 1000 NDC 53489-564-10 Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablets 7.5 mg, oval, green, double-scored, debossed MP 442 on one side; the other side plain Bottles of 100 NDC 53489-565-01 Bottles of 250 NDC 53489-565-03 Bottles of 500 NDC 53489-565-05 Bottles of 1000 NDC 53489-565-10 Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablets 10 mg, round, green, double-scored, debossed MP 443 on one side; the other side plain Bottles of 100 NDC 53489-566-01 Bottles of 250 NDC 53489-566-03 Bottles of 500 NDC 53489-566-05 Bottles of 1000 NDC 53489-566-10 Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablets 12.5 mg, round, yellow, double-scored, debossed MP 444 on one side; the other side plain Bottles of 100 NDC 53489-567-01 Bottles of 250 NDC 53489-567-03 Bottles of 500 NDC 53489-567-05 Bottles of 1000 NDC 53489-567-10 Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablets 15 mg, oval, yellow, double-scored, debossed MP 445 on one side; the other side plain Bottles of 100 NDC 53489-568-01 Bottles of 250 NDC 53489-568-03 Bottles of 500 NDC 53489-568-05 Bottles of 1000 NDC 53489-568-10 Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablets 20 mg, round, yellow, double-scored, debossed MP 446 on one side; the other side plain Bottles of 100 NDC 53489-569-01 Bottles of 250 NDC 53489-569-03 Bottles of 500 NDC 53489-569-05 Bottles of 1000 NDC 53489-569-10 Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablets 30 mg, round, yellow, double-scored, debossed MP 447 on one side; the other side plain Bottles of 100 NDC 53489-570-01 Bottles of 250 NDC 53489-570-03 Bottles of 500 NDC 53489-570-05 Bottles of 1000 NDC 53489-570-10 Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature] DISPENSE IN TIGHT, LIGHT-RESIStanT CONTAINER.


More pills like ROUND MP 447












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site